Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-generation Proteomics
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced today that they have entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.
Evotec has been a long-term user of Biognosys’ software and kits within its research. The two companies are now working closely together to integrate Biognosys’ next-generation proteomics data analysis platform in drug discovery and clinical proteomics.
Under the extended partnership, Evotec will continue to utilize Spectronaut, Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics, in its research. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types.
Additionally, Evotec is implementing Biognosys’ unique workflow for mass spectrometry facility management. This workflow combines Biognosys’ proprietary QuiC software with its patented indexed Retention Time (iRT) technology and iRT Kit to generate near real-time readouts from mass spectrometry instrument raw files for quality control.
The collaboration uniquely combines Evotec’s partnered drug discovery and development business model and focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transforming drug discovery and development.
Kristina Beeler, PhD, CBO of Biognosys, comments: “We are excited to deploy the power of proteomics to address some of the key challenges of drug development and work closely with Evotec to de-risk therapeutic assets early on.”
Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics at Evotec, comments: “Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the worldleading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005750/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 202513.11.2025 14:23:00 EET | Press release
Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2025. The Group's consolidated turnover in the first nine months of the year reached €1,819.8 million, an increase of 9.0% compared to €1,669.6 million recorded on 30 September 2024. The indicators for the period are positive. Consolidated EBITDA was €335.5 million, equal to 18.4% of the consolidated revenues. As of September 2024 EBITDA was €275.5 million. EBIT, from January to September, reached €281.0 million, equal to 15.4% of the consolidated revenues. The corresponding 2024 figure was €224.2 million. Pre-tax profit, from January to September 2025, was €268.1 million, equal to 14.7% of the revenues. As of September 2024 pre-tax profit stood at €216.0 million. For the third quarter of the year, the Group’s performance is positive, with consolidated turnover for the period of €598.5 million compared to €553.8 million of the third quarter 2024. EBITDA, from July to September 2025, was equa
Hilton Again Named No. 1 World’s Best Workplace13.11.2025 14:16:00 EET | Press release
Once again named the No. 1 World’s Best Workplace by Fortune and Great Place to Work,Hilton (NYSE: HLT) today is releasing findings of a newly commissioned study linking the role of employee experience to consumer purchasing decisions and service experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112613594/en/ Courtesy of Hilton According to a new survey conducted by Morning Consult for Hilton*: Nearly 80% of U.S. consumers (78%) say that companies that take good care of their employees provide better products and services, with nearly 90% (88%) saying that taking care of employees is especially important for travel and hospitality brands. Three out of every four U.S. consumers (75%) say they are more likely to recommend doing business with a company that is known to treat its employees well. Hilton’s commitment to providing a strong workplace culture, which for a decade has landed it on the World’s Best Workplac
Prime Minister Oversees Signing of 55 Pacts in Major Push for Egypt’s Offshoring Industry13.11.2025 14:08:00 EET | Press release
Under the patronage of H.E. Dr. Mostafa Madbouly, Prime Minister of Egypt, the Information Technology Industry Development Agency (ITIDA) announced the signing of 55 strategic agreements with leading multinational and local technology companies in offshoring and IT-enabled services, including Teleperformance, Accenture, Deloitte, VOIS, Luxoft, RSA, and Capgemini. The ceremony, attended by H.E. Dr. Mostafa Madbouly and Dr. Amr Talaat, Minister of Communications and Information Technology, gathered senior representatives, highlighting Egypt’s growing role as a hub for global business services supported by skilled talent, robust infrastructure, and cost competitiveness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113033856/en/ ITIDA signed agreements with multinational and local companies (Photo: AETOSWire) These partnerships will create thousands of high-value jobs for Egyptian youth in business process outsourcing (BPO)
RSA Announces New Solution to Enhance Security for Microsoft Entra ID13.11.2025 14:00:00 EET | Press release
RSA, the security-first identity leader, announced today that RSA® ID Plus for Microsoft, a new solution category that provides an enhanced security layer for Microsoft Entra ID, is now generally available. Now on the Microsoft Azure Marketplace, the first product, RSA ID Plus M1, includes key capabilities that defend organizations from emerging attacks and help them maintain operational continuity in both Microsoft and non-Microsoft environments. RSA ID Plus for Microsoft M1: Protects resources within and beyond the Microsoft ecosystem: RSA ID Plus provides total coverage for legacy, OT, Microsoft, and non-Microsoft environments, bringing modern MFA and passwordless to data centers, mainframes, macOS, AD-joined devices, Entra-joined PCs and servers (including older OS versions), and other web servers and critical infrastructure that Entra alone can’t reach. Ensures mission-critical resources are always available and always protected: RSA’s unique Hybrid HA architecture and offline cap
Dubai Electricity and Water Authority PJSC Announces Record Breaking Revenue of AED 25 Billion and Operating Profit of AED 8.3 billion for the First Nine Months Ending Sept 202513.11.2025 12:19:00 EET | Press release
Dubai Electricity and Water Authority PJSC: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112162153/en/ HE Saeed Mohammed Al Tayer, MD & CEO of DEWA (Photo: AETOSWire) Record nine months of 2025 Results AED 24.9 billion AED 13.1 billion AED 8.3 billion AED 6.8 billion +5.9% YoY +11.9% YoY +21.5% YoY +24.8% YoY 9 months of 2025 Revenue 9 months of 2025 EBITDA 9 months of 2025 Operating Profit 9 months of 2025 Profit After Tax * figures are rounded Record Q3 2025 Results AED 10.3 billion AED 6.2 billion AED 4.6 billion AED 3.9 billion +4.5% YoY +20.4% YoY +29.8% YoY +35% YoY Q3, 2025 Revenue Q3, 2025 EBITDA Q3, 2025 Operating Profit Q3, 2025 Profit After Tax * figures are rounded Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its consolidated financia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom